Bent U. Frandsen, Chief Executive Officer
Education: Bent U. Frandsen holds a Master’s degree in Finance and Strategic Planning from Copenhagen Business School, Denmark.
Previous assignments/engagements: Bent U. Frandsen has about 30 years of professional experience in management, finance, and business development positions in multinational companies, including more than 25 years life science experience at public listed companies such as Lundbeck, ALK-Abelló, Coloplast, and private companies such as NsGene, CMC Biologics, and Amphidex. Bent U. Frandsen was a board member in AdaptVac Aps.
Mr. Frandsen is experienced in licensing, services, M&A, and new cash deals in excess of €200 million, and has furthermore been in charge of successfully closing numerous collaboration agreements pertaining to research and development of both new chemical entities and biologicals.
Other material ongoing positions: CEO of ExpreS2ion Biotechnologies ApS.
He has been employed by ExpreS2ion since 2016 and was appointed CEO in 2019.
Keith Alexander, Chief Financial Officer
Education: Keith Alexander holds an MBA from The Wharton School of the University of Pennsylvania, and a B.Sc. in Industrial Management, with a minor in Biological Sciences, from Purdue University.
Previous assignments/engagements: Keith Alexander has over 25 years of professional experience in investment markets, investor communications, corporate strategy, and business development from American and Danish banks. Over his career, he has served in leadership, analytical and commercial functions at J.P. Morgan Securities and J.P. Morgan Asset Management in NY, the US, Danske Bank Asset Management (formerly Danske Capital) in Kongens Lyngby, Denmark and Accenture (formerly Andersen Consulting) in Chicago, IL, the US.
Mr. Alexander has contributed to raising over €1 billion for equity and bond portfolios, evaluated large M&A transactions, structured and valued cross-border joint ventures, advised investors managing over $8 trillion in assets, and analyzed financial services companies as a member of the #1 ranked All-American Equity Research Team in 2010 at J.P. Morgan Securities.
He has been employed by the Company since October 2020 and is an American citizen with Danish permanent residence.
Dr. Farshad Guirakhoo, Chief Scientific Officer
Education: Dr. Guirakhoo holds a PhD in Virology from the Medical University of Vienna, Austria, and an M.Sc. in Genetics from the International Institute for Biophysics and Biochemistry at the University of Tehran.
Previous assignments/engagements: Dr. Guirakhoo has 30+years of broad translational research experience in the vaccine development field. He joins from his recent positions as Senior Advisor Vaccine Research and Development and CSO of Vaxxinity, Inc. (NASDAQ: VAXX), headquartered in Dallas, Texas. In 2014, Dr. Guirakhoo was named as no. 22 in The Most Influential People in Vaccines. He is the co-inventor of the ChimeriVax™-technology platform, the world’s first recombinant viral vector platform that was approved for any human vaccine. Dr. Guirakhoo has broad experience in the application of genetics, gene expression technologies and molecular virology for the construction and production of recombinant proteins, human antibodies and attenuated viral vectored vaccines for prevention and treatment of infectious diseases and cancers. He is the author of over 100 peer-reviewed publications and holds dozens of issued patents.
Dr. Guirakhoo has been employed by the company since January of 2023.
Dr. Mattis Flyvholm Ranthe, Chief Medical Officer
Education: Dr. Mattis F. Ranthe holds a Doctor of Medicine and a PhD in cardiovascular epidemiology from the University of Copenhagen Denmark and a MSc in drug development from Kings´ College, London.
Previous assignments/engagements: Dr. Mattis F. Ranthe has extensive experience with drug development from headquarter positions in global pharma, backed up by broad clinical experience. He has in total of more than ten years´ combined research experience from academia/pharma, from, among other things, his time as Medical Director at ALK and Senior clinical research & development lead at GSK Vaccines. Dr. Mattis F. Ranthe has experience in drug development from preclinical/FTiH transition, and all the way to approval/LCM.
Dr. Ranthe has been employed by the company since February of 2022.
Dr. Max M. Søgaard, Senior Vice President of Research & Development and Technology
Education: Dr. Søgaard holds a PhD in Biochemistry from University College London, UK, and a MSc in Molecular Biology from Aarhus University, Denmark.
Previous assignments/engagements: Dr. Søgaard has 20 years of scientific research and process development experience, having served the last eight years at ExpreS2ion in roles ranging from Senior Scientist (Downstream) to Vice President, and prior to that 12 years of academic research focused on structural biology and molecular biophysics with an emphasis on infectious disease applications. Max heads internal R&D in order to extend ExpreS2ion’s capabilities and know-how in applying ExpreS2™ technology for customers and the company’s own vaccine development.
Dr. Søgaard has been employed by the Company since 2013.
Dr. Mette Thorn, Senior Vice President of Preclinical Development
Education: Dr. Thorn holds a PhD in Immunology and a MSc in Chemical Engineering from the Technical University of Denmark.
Previous assignments/engagements: Dr. Thorn has 20 years of preclinical development and management experience in vaccine development within cancer and infectious diseases, amongst other fields. Mette Thorn has extensive research science experience from Biotech and Pharma, including from roles with Astion Pharma, the SSI, Symphogen, Novo Nordisk, Bioneer, Biocare, and CBio. In all of her roles she has been instrumental in progressing preclinical pipeline assets from early stage research into clinical development phases. Mette Thorn was previously CSO for Biocare Copenhagen and Associate Manager of Novo Nordisk Pharmatech.
Other material ongoing positions: Owner of STABIL.solutions.
Dr. Thorn has been employed by the company since February of 2021.